|
1.
|
|
15 p, 3.7 MB |
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
/
Botta, Cirino (Clínica Universidad de Navarra) ;
Perez, Cristina (Clínica Universidad de Navarra) ;
Larrayoz, Marta (Clínica Universidad de Navarra) ;
Puig, Noemí (Hospital Universitario de Salamanca) ;
Cedena, María Teresa (Hospital Universitario 12 de Octubre) ;
Termini, Rosalinda (Clínica Universidad de Navarra) ;
Goicoechea, Ibai (Clínica Universidad de Navarra) ;
Rodriguez, Sara (Clínica Universidad de Navarra) ;
Zabaleta, Aintzane (Clínica Universidad de Navarra) ;
Lopez, Aitziber (Clínica Universidad de Navarra) ;
Sarvide, Sarai (Clínica Universidad de Navarra) ;
Blanco, Laura (Clínica Universidad de Navarra) ;
Papetti, Daniele Marco (Department of Informatics. University of Milano-Bicocca) ;
Nobile, M.S. (Biostatistics and Bioimaging Centre-B4) ;
Besozzi, Daniela (Biostatistics and Bioimaging Centre-B4) ;
Gentile, Massimo (Department of Oncohematology. "Annunziata" Hospital) ;
Correale, Pierpaolo (Great Metropolitan Hospital "Riuniti" of Reggio Calabria) ;
Siragusa, Sergio (Department of Health Promotion. University of Palermo) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-Garcia, Maria Esther (Hospital Universitario de Cabueñes (Gijón)) ;
Sureda, Anna (Institut d'Investigació Biomèdica de Bellvitge) ;
de Arriba, Felipe (Instituto Murciano de Investigación Biosanitaria) ;
Ríos-Tamayo, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Moraleda, José María (Instituto Murciano de Investigación Biosanitaria) ;
Gironella, Mercedes (Hospital Universitari Vall d'Hebron) ;
Hernández, Miguel T. (Hospital Universitario de Canarias (Illes Canàries)) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Palomera, Luís (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Pérez-Montaña, Albert (Hospital Universitari Son Espases (Illes Balears)) ;
Goldschmidt, Hartmut (Department of Internal Medicine V. University of Heidelberg) ;
Avet-Loiseau, Hervé (IUC-T Oncopole) ;
Roccaro, Aldo (Department of Hematology. ASST Spedali Civili di Brescia) ;
Orfao, Alberto (Universidad de Salamanca. Departament de Medicina) ;
Martinez-Lopez, Joaquín (Hospital Universitario 12 de Octubre) ;
Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lahuerta, J. J (Hospital Universitario 12 de Octubre) ;
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Mateos, M. V (Hospital Universitario de SalamancaBiomedica de Salamanca (IBSAL). Centro de Investigación del Cancer (IBMCC-USAL. CSIC)) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Martinez Climent, Juan-José (Clínica Universidad de Navarra) ;
Paiva, Bruno (Clínica Universidad de Navarra)
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). [...]
2023 -  10.1038/s41467-023-41562-6
Nature communications, Vol. 14 Núm. 1 (december 2023) , p. 5825
|
|
|
2.
|
|
13 p, 1.2 MB |
Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy : A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research
/
Schoettler, M.L. (Children's Healthcare of Atlanta) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cho, Byung-Sik (The Catholic University of Korea) ;
Dandoy, Christopher E. (Cincinnati Children's Hospital Medical Center) ;
Ho, Vincent Trien Vinh (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Jodele, Sonata (Cincinnati Children's Hospital Medical Center) ;
Moissev, I. (Pavlov First Saint Petersburg State Medical University) ;
Sańchez Ortega, Isabel (European Society for Bone Marrow Transplant) ;
Srivastava, Alok (Christian Medical College Vellore) ;
Atsuta, Yoshiko (Aichi Medical University) ;
Carpenter, Paul A. (Seattle Children's Hospital) ;
Koreth, John (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Kröger, Nicolaus M. (Ohio State. University) ;
Ljungman, Per (Karolinska Institutet (Estocolm, Suècia)) ;
Page, Kristin M. (Medical College of Wisconsin) ;
Popat, Uday R. (The University of Texas MD Anderson Cancer Center) ;
Shaw, Bronwen E. (Medical College of Wisconsin) ;
Sureda Balari, Anna Maria (Institut Catala d'Oncologia-Hospital Duran i Reynals) ;
Soiffer, Robert J. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Vasu, Sumithira V. (Ohio State. University)
Transplantation-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of hematopoietic cell transplantation (HCT) associated with significant morbidity and mortality. [...]
2023 - 10.1016/j.jtct.2022.11.015
Transplantation and Cellular Therapy, Vol. 29 Núm. 3 (march 2023) , p. 151-163
|
|
|
3.
|
|
12 p, 1.6 MB |
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
/
Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Hebraud, Benjamin (Institut Universitaire du Cancer de Toulouse-Oncopole) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Colin, Anne-Laurène (Ser Centre Hospitalier et Universitaire de Toulouse) ;
Ríos Tamayo, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Hulin, Cyrille (Department of Hematology. Hôpital Haut-Lévêque) ;
Blanchard, María Jesús (Hospital Ramón y Cajal) ;
Caillot, Denis (Hôpital du Bocage) ;
Sureda, Anna (Universitat de Barcelona) ;
Hernández, Miguel Teodoro (Hospital Universitario de Canarias (La Laguna)) ;
Arnulf, Bertrand (Hôpital St-Louis) ;
Mateos, M. V (Instituto de Investigación Biomédica de Salamanca) ;
Macro, Margaret (Centre Hospitalier et Universitaire de Caen) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Belhadj, Karim (Centre Hospitalier et Universitaire Henri Mondor) ;
Lahuerta, J. J (Clínica Universidad de Navarra) ;
Garelik, M.Brigid (Bristol-Myers Squibb Company) ;
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France)
Objective: Providing the most efficacious frontline treatment for newly diagnosed multiple myeloma (NDMM) is critical for patient outcomes. No direct comparisons have been made between bortezomib + lenalidomide + dexamethasone (VRD) and bortezomib + thalidomide + dexamethasone (VTD) induction regimens in transplant-eligible NDMM. [...]
2023 - 10.3389/fonc.2023.1197340
Frontiers in Oncology, Vol. 13 (2023) , p. 1197340
|
|
|
4.
|
|
9 p, 1.2 MB |
Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma
/
Gonzalez Montes, Yolanda (Universitat de Girona) ;
Rodriguez-Romanos, Rocío (Universitat de Girona) ;
Villavicencio, Alicia (Universitat de Girona) ;
Osca Gelis, Gemma (Universitat de Girona) ;
González-Bártulos, Marta (Universitat de Girona) ;
Llopis, Francesca (Universitat de Girona) ;
Clapes, Victòria (Hospital Universitari de Bellvitge) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sureda, Anna (Hospital Universitari de Bellvitge) ;
Escoda, Lourdes (Universitat Rovira i Virgili) ;
Sarrà, Josep (Universitat Rovira i Virgili) ;
Garzó, Ana (Universitat de Girona) ;
Lloveras, Natàlia (Universitat de Girona) ;
Díez, Isabel (Universitat de Girona) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gallardo, David (Universitat de Girona)
Immune dysfunction in patients with multiple myeloma (MM) affects both the innate and adaptive immune system. Molecules involved in the immune checkpoint pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. [...]
2023 - 10.3389/fimmu.2023.1158105
Frontiers in immunology, Vol. 14 (april 2023)
|
|
|
5.
|
|
4 p, 756.5 KB |
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma : final analysis of PLEIADES and EQUULEUS
/
Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu, France) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai, New York, USA) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Haenel, M. (Klinikum Chemnitz, Germany) ;
Touzeau, Cyrille (University Hospital Hôtel-Dieu, France) ;
Ailawadhi, Sikander (Mayo Clinic Florida, USA) ;
Besemer, Britta (Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Germany) ;
de la Rubia Comos, Javier (Catholic University of Valencia) ;
Encinas, Cristina (Hospital General Universitario Gregorio Marañón) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
Salwender, Hans (AK Altona and AK St. Georg, Hamburg, Germany) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Hulin, Cyrille (Hôpital Haut Lévêque. University Hospital, Pessac, France) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud. Hospices Civils de Lyon, France) ;
Sureda Balari, Anna (Institut d'Investigació Biomèdica de Bellvitge) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Benboubker, Lotfi (Centre Hospitalier Régional Universitaire (CHRU), France) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Tarantolo, Stefano (Nebraska Cancer Specialists, Omaha, USA) ;
Terebelo, Howard (Providence Cancer Center, Southfield, USA) ;
Yang, Shiyi (Janssen Research & Development. LLC, USA) ;
Wang, Jianping (Janssen Research & Development. LLC, USA) ;
Nnane, Ivo (Janssen Research & Development. LLC, USA) ;
Qi, Ming (Janssen Research & Development. LLC, USA) ;
Kosh, Michele (Janssen Research & Development. LLC, USA) ;
Delioukina, Maria (Janssen Research & Development. LLC, USA) ;
Goldschmidt, Hartmut (GMMG-Study Group at University Hospital Heidelberg, Germany)
2023 - 10.1038/s41408-023-00805-x
Blood Cancer Journal, Vol. 13 Núm. 1 (march 2023)
|
|
|
6.
|
|
10 p, 680.7 KB |
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma
/
Ahmed, Sairah (University of Texas) ;
Kanakry, Jennifer A. (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ;
Ahn, Kwang Woo (Medical College of Wisconsin) ;
Litovich, Carlos Alejandro (Medical College of Wisconsin) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Aljurf, Mahmoud Deeb (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Bacher, Vera Ulrike (Inselspital. Bern University Hospital) ;
Bejanyan, Nelli (Immunotherapy. Moffitt Cancer Center) ;
Cohen, Jonathon B. (Emory University School of Medicine) ;
Farooq, Umar (University of Iowa Hospitals and Clinics) ;
Fuchs, Ephraim Joseph (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) ;
Bolaños-Meade, Javier (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) ;
Ghosh, Nilanjan S. (Levine Cancer Institute. Atrium Health) ;
Herrera, Alex F. (City of Hope National Medical Center) ;
Hossain, Nasheed (Loyola University Chicago-Stritch School of Medicine) ;
Inwards, David (Mayo Clinic) ;
Kanate, Abraham Sebastian (West Virginia University) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Munshi, Pashna (Georgetown University Hospital) ;
Murthy, Hemant S. (University Florida College of Medicine) ;
Mussetti, Alberto (Institut Català d'Oncologia-Hospitalet) ;
Nieto, Yago (University of Texas) ;
Perales, Miguel-Angel (Memorial Sloan Kettering Cancer Center) ;
Romee, Rizwan (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Seo, Sachiko (Dokkyo Medical University) ;
Wirk, Baldeep Mona (Seattle Cancer Care Alliance) ;
Yared, Jean A. (University of Maryland) ;
Sureda, Anna (Institut Català d'Oncologia-Hospitalet) ;
Fenske, Timothy S. (Medical College of Wisconsin) ;
Hamadani, Mehdi (Medical College of Wisconsin) ;
Universitat Autònoma de Barcelona
Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning (RIC) HCT platforms in cHL: T cell-replete related donor haploidentical (haplo) HCT with a post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin inhibitor (CNI)-based approach. [...]
2019 - 10.1016/j.bbmt.2019.05.025
Biology of blood and marrow transplantation, Vol. 25 Núm. 9 (september 2019) , p. 1859-1868
|
|
|
7.
|
|
11 p, 893.9 KB |
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
/
Piñana, José Luis (Fundación INCLIVA. Instituto de Investigación Sanitaria Hospital Clínico Universitario de Valencia) ;
López-Corral, Lucía (Hospital Clínico Universitario (Salamanca)) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Vazquez, Lourdes (Hospital Clínico Universitario (Salamanca)) ;
Pérez, Ariadna (Fundación INCLIVA. Instituto de Investigación Sanitaria Hospital Clínico Universitario de Valencia) ;
Martin-Martin, Gabriel Andres (Hospital Clínico Universitario (Salamanca)) ;
Gago, Beatriz (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Sanz-Linares, Gabriela (Institut d'Investigació Biomèdica de Bellvitge) ;
Sánchez Salinas, Andrés (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ;
Villalon, Lucia B. (Hospital Universitario Fundación Alcorcón) ;
Conesa-García, Venancio (Hospital General Universitario de Elche) ;
Olave, María Teresa (Hospital Clínico Universitario Lozano Blesa. Instituto de Investigacón Sanitaria Aragón) ;
Corona de Lapuerta, Magdalena (Hospital Universitario Ramón y Cajal (Madrid)) ;
Marcos-Corrales, Sara (Hospital Clínico Universitario (Salamanca)) ;
Tormo, Mar (Instituto de Investigación Sanitaria Fundación Para la Investigación del Hospital Clínico de Valencia) ;
Hernandez-Rivas, JA (Hospital Universitario Infanta Leonor) ;
Montoro, Juan B. (Hospital Universitari i Politècnic La Fe (València)) ;
Rodríguez-Fernández, Alicia (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Risco-Gálvez, Irene (Hospital Arnau de Vilanova (València)) ;
Rodríguez-Belenguer, Pablo (Research Program on Biomedical Informatics (GRIB). Institut Hospital del Mar d'Investigacions Mèdiques. Universitat Pompeu Fabra) ;
Hernandez-Boluda, Juan Carlos (Hospital Clínic Universitari (València)) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Ruíz-García, Montserrat M. (Hospital General Universitario de Elche) ;
Muñoz-Bellido, Juan Luis (Hospital Clínico Universitario (Salamanca)) ;
Solano, Carlos (Hospital Clínic Universitari (València)) ;
Cedillo Cedillo, Angel (Hematopoietic Stem Cell Transplantation and Cell Therapy Group) ;
Sureda, Anna (Institut d'Investigació Biomèdica de Bellvitge) ;
Navarro, David (Hospital Clínic Universitari (València))
Background: The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. Patients and methods: A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021 by the Spanish transplant and cell therapy group was used to analyze the relationship of antibody response at 3-6 weeks after full vaccination (2 doses) with breakthrough SARS-CoV-2 infection in 1394 patients with hematological disorders. [...]
2022 - 10.1186/s13045-022-01275-7
Journal of hematology & oncology, Vol. 15 Núm. 1 (december 2022) , p. 54
|
|
|
8.
|
|
10 p, 856.3 KB |
Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor
/
Sureda, Anna (Institut Català d'Oncologia) ;
Chabannon, Christian (Institut Paoli-Calmettes) ;
Masszi, Tamás (Semmelweis University) ;
Pohlreich, David (Charles University Hospital) ;
Scheid, Christof (University of Cologne) ;
Thieblemont, Catherine (Hôpital Saint-Louis) ;
Wahlin, Björn E. (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Sakellari, Ioanna (George Papanicolaou General Hospital) ;
Russell, Nigel (Nottingham University Hospital) ;
Janikova, Andrea (University Hospital Brno (República Txeca)) ;
Dabrowska-Iwanicka, Anna (Maria Sklodowska-Curie Institute-Oncology Center) ;
Touzeau, Cyrille (CHU Nantes) ;
Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ;
Jantunen, Esa (University of Eastern Finland and Kuopio University Hospital) ;
van der Werf, Steffie (EBMT Data Office) ;
Bosman, Paul (EBMT Data Office) ;
Boumendil, Ariane (EBMT Statistical Unit) ;
Liu, Qianying (Sanofi Genzyme) ;
Celanovic, Marina (Sanofi Genzyme) ;
Montoto, Silvia (St Bartholomew's Hospital) ;
Dreger, Peter (University of Heidelberg) ;
Universitat Autònoma de Barcelona
Plerixafor + granulocyte-colony stimulating factor (G-CSF) is administered to patients with lymphoma who are poor mobilizers of hematopoietic stem cells (HSCs) in Europe. This international, multicenter, non-interventional registry study (NCT01362972) evaluated long-term follow-up of patients with lymphoma who received plerixafor for HSC mobilization versus other mobilization methods. [...]
2020 - 10.1038/s41409-019-0693-z
Bone marrow transplantation, Vol. 55 Núm. 3 (january 2020) , p. 613-622
|
|
|
9.
|
|
2 p, 458.6 KB |
Role of Hospital Exemption in Europe : position paper from the Spanish Advanced Therapy Network
/
Sanchez-Guijo, Fermin (Universidad de Salamanca) ;
Badimon, Lina (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Avendaño Sola, Cristina (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Bueren, Juan (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Canals, Josep M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Delgadillo Duarte, Joaquin (Banc de Sang i Teixits) ;
Delgado, Julio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Eguizábal, Cristina (Instituto de Investigación Sanitaria Biocruces Bizkaia) ;
Fernández-Santos, María-Eugenia (Hospital General Universitario Gregorio Marañón) ;
García-Olmo, Damián (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
González-Aseguinolaza, Gloria (Universidad de Navarra) ;
Juan, Manel (Hospital Clínic i Provincial de Barcelona) ;
Martín, Francisco (Universidad de Granada. Departamento de Bioquímica y Biología Molecular III e Inmunología) ;
Mata, Rosario (Coordination Unit of the Andalusian Network for the Design and Translation of Advanced Therapies) ;
Montserrat, Nuria (Institució Catalana de Recerca i Estudis Avançats) ;
Pérez-Martínez, Antonio (Universidad Autónoma de Madrid) ;
Pérez-Simón, José Antonio (Universidad de Sevilla. Department of Hematology) ;
Prosper, Felipe (Clínica Universidad de Navarra) ;
Urbano Ispizua, Álvaro (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Zapata, Agustín G. (Complutense University. Faculty of Biology. Dept of Cell Biology) ;
Sureda, Anna (Universitat de Barcelona) ;
Moraleda, José María (University of Murcia) ;
Universitat Autònoma de Barcelona
2023 - 10.1038/s41409-023-01962-0
Bone marrow transplantation, Vol. 58 (march 2023) , p. 727-728
|
|
|
10.
|
|
12 p, 600.5 KB |
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
/
Carlo-Stella, Carmelo (Humanitas Research Hospital (Itàlia)) ;
Zinzani, Pier Luigi (IRCCS Azienda Ospedaliero-Universitaria di Bologna) ;
Sureda, Anna (Hospital Universitari de Bellvitge) ;
Araújo, Luis (Universitário de Coimbra) ;
Casasnovas, Olivier (CHU Dijon Bourgogne) ;
Carpio Segura, Cecilia del Carmen (Hospital Universitari Vall d'Hebron) ;
Yeh, Su-Peng (China Medical University Hospital) ;
Bouabdallah, Krimo (University Hospital of Bordeaux) ;
Cartron, Guillaume (Centre Hospitalier Universitaire Montpellier) ;
Kim, Won Seog (Samsung Medical Center) ;
Cordoba, Raul (Hospital Universitario Fundación Jiménez Díaz) ;
Koh, Youngil (Seoul National University Hospital) ;
Re, Alessandro (ASST Spedali Civili Brescia) ;
Alves, Daniela (Centro Hospitalar Universitário Lisboa Norte) ;
Chamuleau, Martine (Vrije Universiteit Amsterdam) ;
Le Gouill, Steven (Institut Curie) ;
López Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ;
Moreira, Ilídia (Portuguese Institute of Oncology of Porto) ;
van der Poel, Marjolein W. M. (Maastricht University Medical Center) ;
Abbadessa, Giovanni (Sanofi) ;
Meng, Robin (Sanofi) ;
Ji, Ran (Sanofi) ;
Lépine, Lucie (Sanofi) ;
Saleem, Rao (Sanofi) ;
Ribrag, Vincent (Institut Gustave Roussy (Villejuif, França)) ;
Universitat Autònoma de Barcelona
Patients with relapsed or refractory lymphoma have limited treatment options, requiring newer regimens. In this Phase 1/2 study (NCT03769181), we assessed the safety, efficacy, and pharmacokinetics of isatuximab (Isa, anti-CD38 antibody) in combination with cemiplimab (Cemi, anti-programmed death-1 [PD-1] receptor antibody; Isa + Cemi) in patients with classic Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), and peripheral T-cell lymphoma (PTCL). [...]
2022 - 10.1002/hon.3089
Hematological Oncology, Vol. 41 (october 2022) , p. 108-119
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
